Does the media favor AMRX or PAHC?

In the previous week, Amneal Pharmaceuticals had 5 more articles in the media than Phibro Animal Health. MarketBeat recorded 7 mentions for Amneal Pharmaceuticals and 2 mentions for Phibro Animal Health. Phibro Animal Health's average media sentiment score of 1.52 beat Amneal Pharmaceuticals' score of 0.95 indicating that Phibro Animal Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amneal Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Phibro Animal Health 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor PAHC or TVTX?

In the previous week, Travere Therapeutics had 2 more articles in the media than Phibro Animal Health. MarketBeat recorded 4 mentions for Travere Therapeutics and 2 mentions for Phibro Animal Health. Phibro Animal Health's average media sentiment score of 1.52 beat Travere Therapeutics' score of 0.99 indicating that Phibro Animal Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phibro Animal Health 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Travere Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ORKA or PAHC?

In the previous week, Oruka Therapeutics had 3 more articles in the media than Phibro Animal Health. MarketBeat recorded 5 mentions for Oruka Therapeutics and 2 mentions for Phibro Animal Health. Phibro Animal Health's average media sentiment score of 1.52 beat Oruka Therapeutics' score of 0.50 indicating that Phibro Animal Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oruka Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Phibro Animal Health 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to PAHC or INDV?

In the previous week, Indivior had 2 more articles in the media than Phibro Animal Health. MarketBeat recorded 4 mentions for Indivior and 2 mentions for Phibro Animal Health. Phibro Animal Health's average media sentiment score of 1.52 beat Indivior's score of 0.42 indicating that Phibro Animal Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phibro Animal Health 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Indivior 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to PAHC or CRSP?

In the previous week, CRISPR Therapeutics had 7 more articles in the media than Phibro Animal Health. MarketBeat recorded 9 mentions for CRISPR Therapeutics and 2 mentions for Phibro Animal Health. Phibro Animal Health's average media sentiment score of 1.52 beat CRISPR Therapeutics' score of 0.71 indicating that Phibro Animal Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phibro Animal Health 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive CRISPR Therapeutics 4 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Phibro Animal Health (PAHC) Competitors

$33.05 -0.26 (-0.78%)

Closing price 04:00 PM Eastern

Extended Trading

$33.70 +0.65 (+1.98%)

As of 05:04 PM Eastern

Compare

PAHC vs. AMRX, TVTX, ORKA, INDV, and CRSP

Should you buy Phibro Animal Health stock or one of its competitors? MarketBeat compares Phibro Animal Health with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Phibro Animal Health include Amneal Pharmaceuticals (AMRX), Travere Therapeutics (TVTX), Oruka Therapeutics (ORKA), Indivior (INDV), and CRISPR Therapeutics (CRSP). These companies are all part of the "pharmaceutical products" industry.

How does Phibro Animal Health compare to Amneal Pharmaceuticals?

Amneal Pharmaceuticals (NASDAQ:AMRX) and Phibro Animal Health (NASDAQ:PAHC) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.

Amneal Pharmaceuticals has higher revenue and earnings than Phibro Animal Health. Phibro Animal Health is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.02B	1.85	$72.06M	$0.38	46.05
Phibro Animal Health	$1.30B	1.03	$48.26M	$2.33	14.18

Phibro Animal Health has a net margin of 6.35% compared to Amneal Pharmaceuticals' net margin of 4.01%. Phibro Animal Health's return on equity of 37.14% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	4.01%	-313.96%	7.49%
Phibro Animal Health	6.35%	37.14%	8.57%

In the previous week, Amneal Pharmaceuticals had 5 more articles in the media than Phibro Animal Health. MarketBeat recorded 7 mentions for Amneal Pharmaceuticals and 2 mentions for Phibro Animal Health. Phibro Animal Health's average media sentiment score of 1.52 beat Amneal Pharmaceuticals' score of 0.95 indicating that Phibro Animal Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amneal Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Phibro Animal Health	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Amneal Pharmaceuticals presently has a consensus target price of $16.60, indicating a potential downside of 5.14%. Phibro Animal Health has a consensus target price of $42.50, indicating a potential upside of 28.59%. Given Phibro Animal Health's higher probable upside, analysts plainly believe Phibro Animal Health is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71
Phibro Animal Health	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Amneal Pharmaceuticals has a beta of 1.26, suggesting that its stock price is 26% more volatile than the broader market. Comparatively, Phibro Animal Health has a beta of 0.46, suggesting that its stock price is 54% less volatile than the broader market.

31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. Comparatively, 99.3% of Phibro Animal Health shares are owned by institutional investors. 17.3% of Amneal Pharmaceuticals shares are owned by company insiders. Comparatively, 50.1% of Phibro Animal Health shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Amneal Pharmaceuticals and Phibro Animal Health tied by winning 8 of the 16 factors compared between the two stocks.

How does Phibro Animal Health compare to Travere Therapeutics?

Phibro Animal Health (NASDAQ:PAHC) and Travere Therapeutics (NASDAQ:TVTX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, profitability, dividends, media sentiment, institutional ownership, valuation, earnings and analyst recommendations.

Phibro Animal Health has a net margin of 6.35% compared to Travere Therapeutics' net margin of -4.00%. Phibro Animal Health's return on equity of 37.14% beat Travere Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phibro Animal Health	6.35%	37.14%	8.57%
Travere Therapeutics	-4.00%	-26.16%	-3.71%

In the previous week, Travere Therapeutics had 2 more articles in the media than Phibro Animal Health. MarketBeat recorded 4 mentions for Travere Therapeutics and 2 mentions for Phibro Animal Health. Phibro Animal Health's average media sentiment score of 1.52 beat Travere Therapeutics' score of 0.99 indicating that Phibro Animal Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phibro Animal Health	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Travere Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.3% of Phibro Animal Health shares are owned by institutional investors. 50.1% of Phibro Animal Health shares are owned by company insiders. Comparatively, 4.4% of Travere Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Phibro Animal Health has a beta of 0.46, suggesting that its share price is 54% less volatile than the broader market. Comparatively, Travere Therapeutics has a beta of 1.1, suggesting that its share price is 10% more volatile than the broader market.

Phibro Animal Health presently has a consensus price target of $42.50, indicating a potential upside of 28.59%. Travere Therapeutics has a consensus price target of $52.08, indicating a potential downside of 6.11%. Given Phibro Animal Health's higher possible upside, research analysts clearly believe Phibro Animal Health is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phibro Animal Health	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Travere Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

Phibro Animal Health has higher revenue and earnings than Travere Therapeutics. Travere Therapeutics is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phibro Animal Health	$1.30B	1.03	$48.26M	$2.33	14.18
Travere Therapeutics	$490.73M	10.51	-$25.55M	-$0.23	N/A

Summary

Phibro Animal Health beats Travere Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Phibro Animal Health compare to Oruka Therapeutics?

Oruka Therapeutics (NASDAQ:ORKA) and Phibro Animal Health (NASDAQ:PAHC) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations, institutional ownership and media sentiment.

Oruka Therapeutics has a beta of -0.35, meaning that its stock price is 135% less volatile than the broader market. Comparatively, Phibro Animal Health has a beta of 0.46, meaning that its stock price is 54% less volatile than the broader market.

Oruka Therapeutics presently has a consensus target price of $134.30, indicating a potential upside of 46.44%. Phibro Animal Health has a consensus target price of $42.50, indicating a potential upside of 28.59%. Given Oruka Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Oruka Therapeutics is more favorable than Phibro Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Phibro Animal Health	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Phibro Animal Health has higher revenue and earnings than Oruka Therapeutics. Oruka Therapeutics is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oruka Therapeutics	N/A	N/A	-$105.43M	-$1.94	N/A
Phibro Animal Health	$1.30B	1.03	$48.26M	$2.33	14.18

56.4% of Oruka Therapeutics shares are held by institutional investors. Comparatively, 99.3% of Phibro Animal Health shares are held by institutional investors. 23.5% of Oruka Therapeutics shares are held by company insiders. Comparatively, 50.1% of Phibro Animal Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Oruka Therapeutics had 3 more articles in the media than Phibro Animal Health. MarketBeat recorded 5 mentions for Oruka Therapeutics and 2 mentions for Phibro Animal Health. Phibro Animal Health's average media sentiment score of 1.52 beat Oruka Therapeutics' score of 0.50 indicating that Phibro Animal Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oruka Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Phibro Animal Health	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Phibro Animal Health has a net margin of 6.35% compared to Oruka Therapeutics' net margin of 0.00%. Phibro Animal Health's return on equity of 37.14% beat Oruka Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oruka Therapeutics	N/A	-26.16%	-25.00%
Phibro Animal Health	6.35%	37.14%	8.57%

Summary

Phibro Animal Health beats Oruka Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Phibro Animal Health compare to Indivior?

Phibro Animal Health (NASDAQ:PAHC) and Indivior (NASDAQ:INDV) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, dividends and earnings.

99.3% of Phibro Animal Health shares are held by institutional investors. Comparatively, 60.3% of Indivior shares are held by institutional investors. 50.1% of Phibro Animal Health shares are held by insiders. Comparatively, 0.7% of Indivior shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Phibro Animal Health currently has a consensus target price of $42.50, suggesting a potential upside of 28.59%. Indivior has a consensus target price of $40.29, suggesting a potential upside of 2.98%. Given Phibro Animal Health's higher possible upside, equities analysts plainly believe Phibro Animal Health is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phibro Animal Health	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Indivior	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75

Indivior has lower revenue, but higher earnings than Phibro Animal Health. Phibro Animal Health is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phibro Animal Health	$1.30B	1.03	$48.26M	$2.33	14.18
Indivior	$1.24B	3.85	$210M	$1.95	20.06

Phibro Animal Health has a beta of 0.46, meaning that its stock price is 54% less volatile than the broader market. Comparatively, Indivior has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market.

In the previous week, Indivior had 2 more articles in the media than Phibro Animal Health. MarketBeat recorded 4 mentions for Indivior and 2 mentions for Phibro Animal Health. Phibro Animal Health's average media sentiment score of 1.52 beat Indivior's score of 0.42 indicating that Phibro Animal Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phibro Animal Health	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Indivior	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Indivior has a net margin of 19.44% compared to Phibro Animal Health's net margin of 6.35%. Phibro Animal Health's return on equity of 37.14% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phibro Animal Health	6.35%	37.14%	8.57%
Indivior	19.44%	-219.26%	29.40%

Summary

Indivior beats Phibro Animal Health on 9 of the 16 factors compared between the two stocks.

How does Phibro Animal Health compare to CRISPR Therapeutics?

Phibro Animal Health (NASDAQ:PAHC) and CRISPR Therapeutics (NASDAQ:CRSP) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership.

In the previous week, CRISPR Therapeutics had 7 more articles in the media than Phibro Animal Health. MarketBeat recorded 9 mentions for CRISPR Therapeutics and 2 mentions for Phibro Animal Health. Phibro Animal Health's average media sentiment score of 1.52 beat CRISPR Therapeutics' score of 0.71 indicating that Phibro Animal Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phibro Animal Health	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
CRISPR Therapeutics	4 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Phibro Animal Health has a beta of 0.46, suggesting that its stock price is 54% less volatile than the broader market. Comparatively, CRISPR Therapeutics has a beta of 1.71, suggesting that its stock price is 71% more volatile than the broader market.

Phibro Animal Health has a net margin of 6.35% compared to CRISPR Therapeutics' net margin of -13,856.54%. Phibro Animal Health's return on equity of 37.14% beat CRISPR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phibro Animal Health	6.35%	37.14%	8.57%
CRISPR Therapeutics	-13,856.54%	-25.66%	-20.39%

Phibro Animal Health currently has a consensus target price of $42.50, indicating a potential upside of 28.59%. CRISPR Therapeutics has a consensus target price of $67.78, indicating a potential upside of 44.24%. Given CRISPR Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe CRISPR Therapeutics is more favorable than Phibro Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phibro Animal Health	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
CRISPR Therapeutics	1 Sell rating(s)	7 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.58

99.3% of Phibro Animal Health shares are held by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are held by institutional investors. 50.1% of Phibro Animal Health shares are held by insiders. Comparatively, 4.3% of CRISPR Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Phibro Animal Health has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phibro Animal Health	$1.30B	1.03	$48.26M	$2.33	14.18
CRISPR Therapeutics	$3.51M	1,291.22	-$581.60M	-$6.22	N/A

Summary

Phibro Animal Health beats CRISPR Therapeutics on 10 of the 17 factors compared between the two stocks.

Get Phibro Animal Health News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PAHC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PAHC vs. The Competition

Export

Metric	Phibro Animal Health	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.34B	$8.65B	$6.78B	$12.28B
Dividend Yield	1.44%	2.49%	2.67%	9.36%
P/E Ratio	14.18	16.04	27.12	23.98
Price / Sales	1.03	7.08	572.82	112.50
Price / Cash	10.19	18.55	29.05	48.09
Price / Book	4.69	3.26	10.65	6.14
Net Income	$48.26M	$228.02M	$3.59B	$331.63M
7 Day Performance	0.15%	-2.84%	-1.61%	-1.68%
1 Month Performance	3.77%	-1.94%	1.01%	-1.40%
1 Year Performance	12.38%	-0.52%	23.83%	17.10%

Phibro Animal Health Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PAHC Phibro Animal Health	4.8304 of 5 stars	$33.05 -0.8%	$42.50 +28.6%	+13.3%	$1.34B	$1.30B	14.18	2,475	Positive News
AMRX Amneal Pharmaceuticals	2.5312 of 5 stars	$16.69 -2.9%	$15.80 -5.3%	+124.0%	$5.32B	$3.02B	43.92	8,500	News Coverage
TVTX Travere Therapeutics	1.9754 of 5 stars	$57.06 +1.4%	$52.08 -8.7%	+252.0%	$5.31B	$490.73M	N/A	460
ORKA Oruka Therapeutics	3.1586 of 5 stars	$87.47 +3.4%	$134.30 +53.5%	+537.6%	$5.28B	N/A	N/A	N/A
INDV Indivior	2.2826 of 5 stars	$40.23 +0.0%	$40.29 +0.1%	+153.2%	$4.90B	$1.24B	20.63	1,051

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PAHC) was last updated on 7/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Phibro Animal Health (PAHC) Competitors

PAHC vs. AMRX, TVTX, ORKA, INDV, and CRSP

How does Phibro Animal Health compare to Amneal Pharmaceuticals?

Summary

How does Phibro Animal Health compare to Travere Therapeutics?

Summary

How does Phibro Animal Health compare to Oruka Therapeutics?

Summary

How does Phibro Animal Health compare to Indivior?

Summary

How does Phibro Animal Health compare to CRISPR Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PAHC vs. The Competition

Phibro Animal Health Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Phibro Animal Health (PAHC) Competitors

PAHC vs. AMRX, TVTX, ORKA, INDV, and CRSP

How does Phibro Animal Health compare to Amneal Pharmaceuticals?

Which has preferable valuation and earnings, AMRX or PAHC?

Is AMRX or PAHC more profitable?

Does the media favor AMRX or PAHC?

Do analysts rate AMRX or PAHC?

Which has more volatility & risk, AMRX or PAHC?

Do institutionals and insiders believe in AMRX or PAHC?

Summary

How does Phibro Animal Health compare to Travere Therapeutics?

Is PAHC or TVTX more profitable?

Does the media favor PAHC or TVTX?

Do insiders and institutionals believe in PAHC or TVTX?

Which has more risk and volatility, PAHC or TVTX?

Do analysts recommend PAHC or TVTX?

Which has stronger earnings & valuation, PAHC or TVTX?

Summary

How does Phibro Animal Health compare to Oruka Therapeutics?

Which has more risk and volatility, ORKA or PAHC?

Do analysts prefer ORKA or PAHC?

Which has stronger valuation and earnings, ORKA or PAHC?

Do insiders & institutionals hold more shares of ORKA or PAHC?

Does the media favor ORKA or PAHC?

Is ORKA or PAHC more profitable?

Summary

How does Phibro Animal Health compare to Indivior?

Do insiders and institutionals have more ownership in PAHC or INDV?

Do analysts recommend PAHC or INDV?

Which has preferable valuation & earnings, PAHC or INDV?

Which has more risk and volatility, PAHC or INDV?

Does the media refer more to PAHC or INDV?

Is PAHC or INDV more profitable?

Summary

How does Phibro Animal Health compare to CRISPR Therapeutics?

Does the media refer more to PAHC or CRSP?

Which has more risk and volatility, PAHC or CRSP?

Is PAHC or CRSP more profitable?

Do analysts prefer PAHC or CRSP?

Do institutionals & insiders hold more shares of PAHC or CRSP?

Which has preferable earnings & valuation, PAHC or CRSP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PAHC vs. The Competition

Phibro Animal Health Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools